Immunodeficiency-associated Hodgkin lymphoma
- 3 June 2021
- journal article
- other
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 14 (6) , 547-559
Abstract
Introduction: Hodgkin lymphoma (HL) can occur in different host conditions, i.e. in the general population and immunocompromised individuals, either during HIV infection or solid organ/hematopoietic transplantation and immunosuppressive drug treatment. Areas covered: Areas covered include multidimensional characteristics of tumor cells and cellular composition of tumor microenvironment of HL. Current conventional treatments and new treatment strategies for HL in immunosuppressed patients, especially in persons living with HIV (PLWH), are also discussed. PubMed and MEDLINE were used for database searches to identify articles in English published from 1989 to 2020. Expert opinion: For people with post-transplant HL or for those with HIV/AIDS-associated HL, standard treatments mirror those in the general population. In the last decade, the combination of cART with anti-neoplastic treatments, alongside with current anti-rejection therapies, has increased long-term survival of people with HL and acquired immune deficiencies. High-dose chemotherapy and autologous stem cell transplantation have been favorably proven as salvage therapy in PLWH with relapsed and refractory HL. Immune checkpoint inhibitors emerged as an area of clinical investigation for relapsed and refractory HL in the general population. Pembrolizumab, an anti-programmed cell death protein 1 (PD-1) drug, resulted safe in PLWH indicating that PD-1 ligand assessment should be advisable in HIV-associated HL.Keywords
Funding Information
- Institutional grant from Centro di Riferimento Oncologico, Aviano for an Intramural Project ‘Agenti infettivi e Tumori’ to A.Carbone and E.Vaccher and by the Italian Ministry of Health (BRI2018)
This publication has 73 references indexed in Scilit:
- Effect of Immune Reconstitution on the Incidence of HIV-Related Hodgkin LymphomaPLOS ONE, 2013
- Successful treatment of a classic Hodgkin lymphoma‐type post‐transplant lymphoproliferative disorder with tailored chemotherapy and Epstein–Barr virus‐specific cytotoxic T lymphocytes in a pediatric heart transplant recipientPediatric Transplantation, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Interim fluoro-2-deoxy-D-glucose–PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infectionAIDS, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Hodgkin's Disease in Patients with HIV InfectionAdvances in Hematology, 2010
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escapeThe Journal of Pathology, 2010
- Pattern of cancer risk in persons with AIDS in Italy in the HAART eraBritish Journal of Cancer, 2009
- Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern EuropeEuropean Journal of Cancer, 2007
- Hodgkin's‐like PTLD versus true Hodgkin's diseasePediatric Transplantation, 2004